Premium
Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer
Author(s) -
Wiggans R. Glen,
Woolley Paul V.,
Macdonald John S.,
Smythe Tarilyn,
Ueno Winston,
Schein Philip S.
Publication year - 1978
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197802)41:2<387::aid-cncr2820410201>3.0.co;2-x
Subject(s) - medicine , nausea , mitomycin c , gastroenterology , regimen , azotemia , vomiting , fluorouracil , streptozotocin , progressive disease , surgery , chemotherapy , diabetes mellitus , endocrinology , renal function
Ten of 23 patients with advanced measurable adenocarcinoma of the pancreas achieved an objective response after treatment with a regimen consisting of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF). The median duration of response is in excess of 7 months, and responding patients have lived significantly longer than patients with progressive disease (7.5+ months vs. 3 months). The SMF regimen was adequately tolerated. Principal toxicities included myelosuppression, which was generally mild, nausea and vomiting. There was reversible nephrotoxicity in the form of proteinuria in 30% of patients and persistent azotemia in 9% of patients.